Fenofibrate

Generic Name
Fenofibrate
Brand Names
Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
Drug Type
Small Molecule
Chemical Formula
C20H21ClO4
CAS Number
49562-28-9
Unique Ingredient Identifier
U202363UOS
Background

Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.

Fenofibrate was granted FDA approval on 31 December 1993.

Indication

Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.

Associated Conditions
Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
Associated Therapies
-
Clinical Trials
Related News

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

First Posted Date
2005-09-16
Last Posted Date
2017-01-12
Lead Sponsor
Stanford University
Target Recruit Count
47
Registration Number
NCT00186537
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Phase 2
Completed
Conditions
Dyslipidaemias
Interventions
Drug: GW590735
Drug: fenofibrate
First Posted Date
2005-09-15
Last Posted Date
2012-10-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
250
Registration Number
NCT00169559
Locations
🇨🇦

GSK Investigational Site, Sainte-Foy, Quebec, Canada

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Phase 3
Terminated
Conditions
Hyperlipoproteinemia Type III
First Posted Date
2005-09-05
Last Posted Date
2012-02-17
Lead Sponsor
Pfizer
Target Recruit Count
41
Registration Number
NCT00145431
Locations
🇨🇦

Pfizer Investigational Site, Quebec, Canada

Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate

Phase 3
Completed
Conditions
Hyperlipidemia
First Posted Date
2005-08-30
Last Posted Date
2007-10-31
Lead Sponsor
Pfizer
Target Recruit Count
128
Registration Number
NCT00139061
Locations
🇫🇷

Pfizer Investigational Site, Tierce, France

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

Phase 2
Completed
Conditions
Hypertriglyceridemia
HIV Infections
First Posted Date
2004-02-04
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
100
Registration Number
NCT00076518
Locations
🇺🇸

The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States

🇺🇸

Case CRS, Cleveland, Ohio, United States

🇺🇸

Ucsf Aids Crs, San Francisco, California, United States

and more 2 locations

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Phase 3
Completed
Conditions
HIV Infections
Lipodystrophy
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
630
Registration Number
NCT00006412
Locations
🇺🇸

Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States

🇺🇸

Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Case Western Reserve Univ, Cleveland, Ohio, United States

and more 55 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy